Mitsubishi Corporation Energy facilitated the trial for Tohoku Electric Power by supplying biofuel in the Keihin area.

Incyclix Bio, LLC, a next-generation cell cycle control company developing INX-315, a novel, potent and selective CDK2 ...

First Solid Tumor Patient Treated with Second, Higher Dose in Phase 1/1b BP1001-A Clinical Trial Experienced Tumor Reduction and Continued Stable ...

Study Progresses to Fourth Higher 90 mg/m2Dose CohortCompelling Patient Response Highlighted by Stable Disease and Significant Reduction in Blast ...

An enzyme called cyclin-dependent kinase 2 (CDK2) regulates the cell cycle and may have the potential to drive therapeutic ...

The Indonesian government is targeting protected forest areas as part of its plan to convert 20 million hectares (50 million ...

HOUSTON - Bio-Path Holdings, Inc. (NASDAQ:BPTH), a biotechnology company with a market capitalization of $3.1 million, has announced continued progress in its clinical trials for cancer treatments.

Accord BioPharma Inc., the U.S. specialty division of Intas Pharmaceuticals Ltd., has reached an exclusive commercialization and license agreement with Bio-Thera Solutions for BAT2506, a biosimilar ...

Find insights on China’s healthcare sector, Thomson Medical Group, Cochlear, and more in the latest Market Talks covering the ...

Boca Raton, Florida Wednesday, February 12, 2025, 16:00 Hrs [IST] ...

Rebranding Invizyne Technologies, Inc to Changing NASDAQ ticker from IZTC to EXOZIntroducing but not trademarking “exozymes” ...